Entrevistas ImunoFoz2011 - Mihály Józsi

SBlogI entrevista:

 

Dra. Mihály K. Józsi

Hans Knöll Institute, Alemanha

SBlogI - What is the theme of your lecture at ImunoFoz 2011?  

Józsi, M. K. - Crosstalk between pentraxins and the complement system.  

SBlogI - What is the main finding or conclusion that will be emphasized?

Józsi, M. K. - While pentraxins activate complement, simultaneously binding complement inhibitors prevent the harmful effects of overwhelming activation. 

SBlogI - What is the significance of this finding? 
Józsi, M. K. - Certain disease-associated variants of complement regulators show reduced pentraxin binding, which is likely involved in pathophysiology.   

SBlogI - What are the future perspectives in this area?

Józsi, M. K. - Role of these interactions  in inflammatory, autoimmune and infectious diseases, and the relevance for therapy should be explored.  

SBlogI - Any suggestions for background reading?

Józsi, M. K. - 

Bottazzi B, Doni A, Garlanda C, Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol. 2010 Mar;28:157-83.

Sjöberg AP, Trouw LA, Blom AM. Complement activation and inhibition: a delicate balance. Trends Immunol. 2009 Feb;30(2):83-90.

Mihlan M, Stippa S, Józsi M, Zipfel PF. Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death Differ. 2009 Dec;16(12):1630-40.

Nauta AJ, Daha MR, van Kooten C, Roos A. Recognition and clearance of apoptotic cells: a role for complement and pentraxins. Trends Immunol. 2003 Mar;24(3):148-54.